can you make money on cryptocurrency searches

The second meeting of the Global Foreign Exchange Market Committee in 2024 was successfully held. From December 5 to December 6, 2024, the second meeting of the Global Foreign Exchange Committee (GFXC) in 2024 was held online. The meeting discussed the promotion and implementation of global standards, the second round of three-year review of global standards, the operation of foreign exchange market and related market hot issues. Representatives from China Foreign Exchange Market Steering Committee (CFXC) attended the meeting. This meeting discussed the final results of the second round of three-year review of global standards. The Working Group on Foreign Exchange Settlement Risk and the Working Group on Foreign Exchange Data respectively introduced the final revision suggestions of the relevant provisions of the global standards, and how the Working Group continuously improved according to the public comments and feedback from the local foreign exchange market committees and in October 2024. The revision of the Global Standards aims to strengthen the relevant principles of foreign exchange settlement risk management and enhance the transparency of specific types of foreign exchange transactions and the use of customer-generated data on electronic trading platforms. GFXC members strongly support this.Shenzhen Holdings: Auditor replacement: PricewaterhouseCoopers resigned and Ernst & Young took over. On December 10th, Shenzhen Holdings (00604.HK) announced that according to Rule 13.51(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, PricewaterhouseCoopers agreed to resign as the auditor of Shenzhen Holdings with effect from December 10th, 2024. At the same time, the board of directors of Shenzhen Holdings decided to appoint Ernst & Young as the new auditor of the company, which will also take effect from December 10, 2024 until the end of the next annual general meeting.Ministry of Finance of Korea: Korea's financial market is still facing uncertainty.

Tang Shikai, a member of the board of directors of Mercedes-Benz, will retire next year and is now in charge of the company's business in Greater China. Mercedes-Benz Group Co., Ltd. announced that Hubertus Troska, the current member of the board of directors in charge of the company's business in Greater China, will retire in 2025 as planned. He himself decided to take up a new position as a member of the board of directors of Mercedes-Benz Group Co., Ltd. and a special representative for China affairs from February 1, 2025 to promote the company's business system in the world's largest market. Tang Shikai will officially retire on July 31, 2025. ZTE and ZTE Xinyun jointly released a digital intelligence financial solution. Recently, ZTE and ZTE Xinyun Cloud Service Co., Ltd. (referred to as "ZTE Xinyun") jointly released a digital intelligence financial solution based on digital nebula. The solution provides one-stop financial cloud application, fully supports financial functions and financial processes, solves breakpoints and pain points in the interaction between industry and finance, breaks the "data island" between systems, realizes the intelligent and efficient collection of business data and financial processing, and empowers the intelligent transformation of enterprise financial data.

Li Ziyuan: There are no matters that should be disclosed but not disclosed. Li Ziyuan issued a change announcement. After the company's self-inspection, the company's current production and operation activities are normal, there is no major adjustment in the market environment or industry policies, and the internal production and operation order is normal; , the company and the controlling shareholder and actual controller of the company have no matters that should be disclosed but not disclosed.The new Indian central bank governor: We have made progress in inclusive finance, but there is still more work to be done; Efforts will be made to further utilize technology without stifling innovation.Hengrui Pharma: HRS-4729 injection was approved for clinical trial. Hengrui Pharma announced that the company and its subsidiary Fujian Sheng Di Pharmaceutical Co., Ltd. received the Notice of Approval for Clinical Trial of HRS-4729 injection approved and issued by National Medical Products Administration. The drug is a polypeptide drug independently developed, and it is a GLP-1R/GIPR/GCGR triple agonist, which is suitable for obese or overweight patients. Up to now, HRS-4729 injection has invested about 19.56 million yuan in research and development.